Enbiosis has made breakthrough in the treatment of irritable bowel syndrome (IBS), with 78% of the IBS patients who followed microbiome-based diets seeing symptoms improve dramatically. Dr. Tarkan Karakan, a gastroenterology specialist who helped conduct the study, said: “We believe this achievement represents a significant step towards demonstrating… Read More
Genetic Analysis has announced a Service Agreement with Eurofins ADME Bioanalysis, a CRO who have launched a standardised gut microbiome test (GA-map Dysbiosis Test). Gut microbiome profiling is required as a surrogate endpoint or exploratory biomarker in clinical trials. This is due to both the impact new pharmaceuticals can… Read More
This is the latest episode of the free DDW podcast: “Opportunities to improve drug discovery systems”. It covers two articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine. The first article is titled “Precision control of protein release… Read More
Microbiome experts from Microba Life Sciences will discuss the next phase of discovery from the microbiome to a global audience via a series of webinars on September 15 (PST 10am-12pm | EST 1-3pm | CET 7pm). Professor Gene Tyson, Associate Professor Lutz Krause and Dr Alena Pribyl will discuss how advancements in metagenomic… Read More
CN Bio has licenced a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University to investigate the direct interaction between the microbiome and gut and the wider effects of the microbiome on organs such as the liver and brain. Planned for commercial… Read More
GlobalData’s report, ‘Thematic Research: Microbiome-Targeted Therapeutics in Immunology’, reveals that 23 microbiome-targeting therapeutics are currently being developed in the US and the 5EU (France, Germany, Italy, Spain, UK) for gastrointestinal (GI), dermatological, and respiratory conditions. Each of these therapies aims to address these diseases by manipulating the microbiome. Microbiome is… Read More
King’s College London is using CNBio’s PhysioMimix Multi-Organ MPS. Following a research collaboration, King’s College London selected the system to create a human-relevant liver-intestinal model for characterising and manipulating host-microbial interactions, to support improved outcomes in cirrhosis. Launched in March 20211, the product combines CN Bio’s in vitro 3D liver… Read More
Genetic Analysis (GA) has announced that the Norwegian Research Council has approved its grant application of NOK 16 million (€1.6 million) for its project developing new innovative microbiome-based diagnostics to be used to aid selection and treatment of Inflammatory Bowel Disease (IBD) patients. In this project, GA will develop an… Read More
4D pharma, a pharmaceutical company looking at the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, has announced a clinical trial collaboration and supply agreement with Merck and Pfizer for BAVENCIO(R) (avelumab), the immunotherapy approved as a first-line maintenance treatment for patients with… Read More
Children under age two who take antibiotics are at greater risk for childhood-onset asthma, respiratory allergies, eczema, coeliac disease, obesity and attention deficit hyperactivity disorder, according to a paper written jointly by Mayo Clinic and Rutgers researchers. In a study published in the journal Mayo Clinic Proceedings, the… Read More
Charlie Badham, Corporate Development, 4D pharma, spoke to Lu Rahman about the growing significance of microbiomics in the quest for new therapeutics LR: How important are microbiomics in the development of new therapeutics and how does understanding gut bacteria help us find treatments for new diseases? CB: The microbiome… Read More
6 July 2020 Image: Science in HD Eremid Research Services is the new name for the commercial arm of research organisation, DHMRI. Eremid continues to specialise in the provision of genomics, metabolomics, NMR and vivarium research services, offering expertise in areas including human health, food & nutrition, and AgBiotech. The company offers a… Read More
25 June 2020 Metabolon and DNA Genotek have teamed up to create OMNImet-GUT, said to be the first device for in-home collection and ambient-temperature storage and shipping of faecal samples for metabolomics, to the research market. “For years, our customers from across biopharma, academia and… Read More
By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in… Read More
By Dr Alexander C. Maue It has become quite evident that the microbiome has the potential to impact drug discovery in vital ways. In addition to impacting study reproducibility and variability, the microbiome may influence drug efficacy or serve as a therapeutic agent. To capitalise on the microbiome’s potential to… Read More
Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic By Dr Sue Grepper, Dr Radina Kostadinova, Dr Eva Thoma and Professor Armin Wolf Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this… Read More